Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Multiple Endocrine Neoplasia Type 1

Endocrine & Hormonal

Multiple Endocrine Neoplasia Type 1 (MEN1) Clinical Trials

Also called MEN1, Wermer syndrome, menin mutation

Multiple endocrine neoplasia type 1 (MEN1), also called Wermer syndrome, is an autosomal dominant cancer predisposition syndrome caused by loss-of-function mutations in the MEN1 gene (chromosome 11q13) encoding menin, a nuclear tumor suppressor protein. Patients develop tumors in multiple endocrine and non-endocrine tissues with tumors typically arising in specific sequence by age.

In plain words, multiple endocrine neoplasia type 1 is an inherited condition that causes tumors in glands that make hormones. These tumors most often grow in the parathyroid glands, the pancreas and the pituitary gland, so lifelong checkups are needed.

Get an email when new Multiple Endocrine Neoplasia Type 1 trials open or the FDA decides. Get alerts

Multiple Endocrine Neoplasia Type 1

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 7 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Multiple Endocrine Neoplasia Type 1 yet.

Multiple Endocrine Neoplasia Type 1 has no FDA-approved medicines, 8 open or active clinical trials (7 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Multiple Endocrine Neoplasia Type 1

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Multiple Endocrine Neoplasia Type 1

The parathyroid glands are involved in >95% of patients, usually the first manifestation (typically by age 20-25), causing primary hyperparathyroidism with hypercalcemia (often 11-13mg/dL), nephrolithiasis (occurs in 20-40% from hypercalciuria), osteoporosis with increased fracture risk, and neuropsychiatric symptoms. Pancreatic/GI neuroendocrine tumors develop in approximately 70% of patients, including gastrin-secreting tumors causing Zollinger-Ellison syndrome (60-70% of pancreatic NETs), insulinomas, non-functional tumors, and pancreatic cancer risk.

Keep reading about Multiple Endocrine Neoplasia Type 1

Pituitary adenomas, particularly prolactin-secreting adenomas (60% of pituitary tumors), develop in 30-40% of patients causing hypogonadism and infertility. Adrenocortical tumors occur frequently (20-40% of patients) though typically nonfunctional. Thyroid adenomas, skin findings (facial angiofibromas, collagenomas, lipomas), carcinoid tumors, and other malignancies increase. Malignant potential varies significantly by tumor type; gastrinomas and pancreatic NETs demonstrate higher malignancy rates.

What are the symptoms of Multiple Endocrine Neoplasia Type 1?

These are common symptoms of Multiple Endocrine Neoplasia Type 1, and how strong they are varies from person to person.

  • Primary hyperparathyroidism with hypercalcemia
  • Gastroenteropancreatic neuroendocrine tumors
  • Pituitary adenomas, often prolactin-secreting
  • Nephrolithiasis from hypercalcemia
  • Carcinoid syndrome from neuroendocrine tumors
  • Bone loss and fracture risk

Who gets Multiple Endocrine Neoplasia Type 1?

Manifestations typically begin by age 20-40 years with hyperparathyroidism often first manifestation. Affects males and females equally with no gender predominance. Autosomal dominant inheritance with high penetrance (95%+ by age 50); offspring of affected parent have 50% risk of inheriting mutation.

Approximately 10% of cases represent new mutations without family history. Disease severity and tumor types vary considerably among affected individuals even within same family. Manifestations may be age-dependent with some tumors developing later in life. All populations affected equally; no ethnic or racial predisposition established.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Multiple Endocrine Neoplasia Type 1

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Multiple Endocrine Neoplasia Type 1 resources

Reputable organizations and medical references for learning more about Multiple Endocrine Neoplasia Type 1, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Multiple Endocrine Neoplasia Type 1

Use this Multiple Endocrine Neoplasia Type 1 clinical trial finder to see the 7 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

8 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT04969926

Natural History Study of Parathyroid Disorders

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Background:

Ages 6 Months to 100 Years1 location
Started Nov 2021Updated 2 days agoEst. Jan 2031 (~4y 2m)
RecruitingTreatment trialPhase 2/3Recently updatedNCT07444723

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Intervention: 18F-FCH, NeuroEXPLORER

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Background:

Ages 18 Years to 100 Years1 location
Started Apr 2026Updated 2 weeks agoEst. Feb 2035 (~8y 2m)
RecruitingPatient registry covering many conditionsRecently updatedNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Sponsor: Sanford Health

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute...

Ages not specified1 location
Started Jul 2010Updated 3 weeks agoEst. Dec 2100 (~74y 2m)
RecruitingPatient registry covering many conditionsUpdated a few months agoNCT03050268

Familial Investigations of Childhood Cancer Predisposition

Sponsor: St. Jude Children's Research Hospital

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local...

Ages not specified1 location
Started Apr 2017Updated 5 months agoEst. Mar 2037 (~10y 4m)
Not yet recruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT06790251

Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)

Sponsor: F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore

The goal of this observational study is to create, manage and analyze a retro-prospective multicenter national database of patients diagnosed with multiple endocrine neoplasia type 1 (MEN1) syndrome (including genetic, clinical and/or familiar diagnosis), aimed at collecting and ...

Ages not specified
Expected to start Jun 2025Updated 1 year agoEst. May 2035 (~8y 6m)
Find Multiple Endocrine Neoplasia Type 1 trials near you, ranked by distance →
Active trial locations3 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Multiple Endocrine Neoplasia Type 1 trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Multiple Endocrine Neoplasia Type 1 foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Multiple Endocrine Neoplasia Type 1 patient communities

Facebook groups, Reddit communities and YouTube channels where Multiple Endocrine Neoplasia Type 1 patients, caregivers and advocacy groups talk.

Questions people ask about Multiple Endocrine Neoplasia Type 1